CE vs EMN: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: CE is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CE and EMN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CE and EMN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Celanese Corporation makes chemicals in two very different businesses. Its Acetyl Chain segment produces acetic acid, vinyl acetate monomer, acetate tow and related derivatives, largely commodity molecules sold on price and cost position, and it generated about ~$2.4B of net sales in the first half of 2026. Engineered Materials, the larger half at roughly ~$2.8B of first-half sales, sells specialty polymers, nylon, elastomers and compounds into automotive, medical, electronics and industrial applications where formulations are specified into a customer's part. Around ~11,400 employees run the plant network, which spans North America, Europe and Asia, with a large equity-affiliate presence in China.

Full CE guide

Eastman Chemical Company (NYSE: EMN) is a global specialty materials producer headquartered in Kingsport, Tennessee, organized into four segments: Advanced Materials (specialty films, plastics, and interlayers), Additives and Functional Products (coatings, inks, and performance additives), Chemical Intermediates (commodity and functional chemicals), and Fibers (cellulose acetate tow, largely for cigarette filters). Annual revenue runs around $9 billion, and the company has leaned into circular-economy positioning through its Kingsport methanolysis (molecular recycling) plant, which converts hard-to-recycle plastic waste back into raw materials and added roughly $60 million of incremental earnings in 2025.

Full EMN guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CE drivers: Deleveraging through cash and asset sales; Acetyl Chain pricing and regional supply dislocation.
• EMN drivers: Molecular recycling ramp; Specialty mix and pricing.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Leverage dominates the risk list. For EMN, eastman is cyclical and sensitive to global industrial demand, energy and raw-material costs, and destocking, all of which pressured 2025 and early 2026 results.

Pick CE if you believe its drivers more; EMN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CE and EMN guides.

CE. Two very different valuations sit on the same company. Equity holders pay roughly half of trailing sales, which looks cheap until the ~$10.6B of net debt is added and the whole enterprise prices at about ~1.7x sales, a fairly ordinary multiple for a chemical producer in a soft cycle. Free cash flow of roughly ~$708M over the trailing twelve months is what services the debt, and first-half operating cash of ~$285M came in below the prior year on a large working-capital build in receivables.

EMN. Eastman trades around $71 per share with a market cap near $8 billion, well below prior highs, reflecting soft recent results and a cyclical backdrop. Q1 2026 sales fell about 5% to ~$2.18 billion and net earnings dropped to ~$107 million, though management guided Q2 adjusted EPS to roughly $1.70 to $1.90. The ~4.5% yield and mid-to-high-teens P/E frame it as a value and income name rather than a growth stock.

Headline figures (approximate, August 2026): CE shows revenue (ttm) ~$9.7B, net income (ttm) ~-$1.2B, driven by goodwill and asset impairments, market cap ~$4.8B at roughly ~$44 per share, net debt ~$10.6B (total debt ~$12.0B less cash ~$1.4B); EMN shows revenue (ttm) ~$9.2B, market cap ~$7.9B, p/e ratio ~18.9, fy2025 adjusted eps ~$5.42.

CE and EMN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CE and EMN exposure against your real portfolio. It is not an investment adviser.